Simulations Plus (SLP) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
10 Jan, 2026Executive summary
Total revenue grew 31% year-over-year to $18.9 million, led by 41% software growth and 19% services growth, with strong contributions from new business units ALI and MC.
Net income was $0.2 million (diluted EPS $0.01), down from $1.9 million (diluted EPS $0.10) in the prior year; adjusted diluted EPS was $0.17.
Adjusted EBITDA was $4.5 million (24% margin), up from $3.4 million (23%) year-over-year.
Software accounted for 57% of revenue; services for 43%.
The acquisition and integration of Pro-ficiency, ALI, and MC expanded the business and portfolio.
Financial highlights
Gross profit was $10.2 million (54% margin), down from 62% in the prior year due to higher costs and mix.
Software gross margin was 75%, services gross margin 26%.
R&D expense was 10% of revenue, sales and marketing 15%, and G&A 28%.
Cash and investments at quarter-end were $18.2 million, with no debt.
Accounts receivable increased to $12.8 million from $9.1 million sequentially.
Outlook and guidance
Fiscal 2025 revenue guidance is $90–$93 million, representing 28%–33% growth, with software mix expected at 55%–60%.
Adjusted EBITDA margin projected at 31%–33%; adjusted diluted EPS guidance is $1.07–$1.20.
Q2 revenue expected to be ~24% of annual guidance, with momentum strongest in the second half.
Guidance excludes future acquisitions; focus remains on integration, cross-selling, and margin improvement.
Latest events from Simulations Plus
- Integrated AI ecosystem and cross-selling drive future growth, with major upside in FY 2027.SLP
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - All proposals passed with strong support; no shareholder questions were raised.SLP
AGM 202612 Feb 2026 - Virtual meeting to vote on directors, auditor, equity plan, and say-on-pay frequency.SLP
Proxy Filing4 Feb 2026 - Pro-ficiency integration and client budget trends drive growth outlook amid ongoing cost constraints.SLP
Stephens 26th Annual Investment Conference | NASH20243 Feb 2026 - $100M acquisition doubles market, expands platform, and boosts 2025 EPS outlook.SLP
M&A Announcement3 Feb 2026 - Q3 revenue up 14% to $18.5M; Pro-ficiency deal and dividend halt shift focus to growth.SLP
Q3 20243 Feb 2026 - Acquisition of Pro-ficiency doubles TAM and accelerates growth in biosimulation and clinical ops.SLP
KeyBanc Capital Markets Technology Leadership Forum2 Feb 2026 - AI, cloud, and validated science converge in a unified platform to accelerate drug development.SLP
Investor Day 202623 Jan 2026 - FY24 revenue up 18% to $70M; FY25 guidance targets up to $93M and higher margins.SLP
Q4 202419 Jan 2026